Alnylam Pharmaceuticals (ALNY) Enterprise Value (2016 - 2025)
Historic Enterprise Value for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Q4 2025 value amounting to -$2.9 billion.
- Alnylam Pharmaceuticals' Enterprise Value fell 826.91% to -$2.9 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$2.9 billion, marking a year-over-year decrease of 826.91%. This contributed to the annual value of -$2.9 billion for FY2025, which is 826.91% down from last year.
- As of Q4 2025, Alnylam Pharmaceuticals' Enterprise Value stood at -$2.9 billion, which was down 826.91% from -$2.7 billion recorded in Q3 2025.
- In the past 5 years, Alnylam Pharmaceuticals' Enterprise Value registered a high of -$1.7 billion during Q1 2021, and its lowest value of -$2.9 billion during Q4 2025.
- For the 5-year period, Alnylam Pharmaceuticals' Enterprise Value averaged around -$2.4 billion, with its median value being -$2.4 billion (2021).
- Data for Alnylam Pharmaceuticals' Enterprise Value shows a peak YoY increase of 861.85% (in 2022) and a maximum YoY decrease of 3358.38% (in 2022) over the last 5 years.
- Quarter analysis of 5 years shows Alnylam Pharmaceuticals' Enterprise Value stood at -$2.4 billion in 2021, then increased by 8.62% to -$2.2 billion in 2022, then fell by 12.08% to -$2.4 billion in 2023, then dropped by 10.63% to -$2.7 billion in 2024, then dropped by 8.27% to -$2.9 billion in 2025.
- Its Enterprise Value stands at -$2.9 billion for Q4 2025, versus -$2.7 billion for Q3 2025 and -$2.9 billion for Q2 2025.